Business
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer. Dr. Adelman is a highly experienced clinical leader and innovator and brings to Jasper more than 30 years of experience in the clinical development of novel therapies for immunologic diseases at Aimmune, Alvine, Sunesis, Pharmacyclics and Genentech. “We are delighted to welcome Dan to the Jasper team as Acting Chief Medical Officer,” said Ron Martell, CEO of Jasper Therapeutics. “Dr. Adelman is an extremely experienced drug developer and leader in the field of immune-based therapeutics and has an impressive track record of success in bringing new drugs to market. His deep knowledge and expertise will be invaluable in advancing our mission of improving patient outcomes through innovative therapies for chronic spontaneous urticaria and other mast cell diseases.\" Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech where he was involved in the early development of omalizumab and bevacizumab. Dr. Adelman has also led the development of other therapies for celiac disease and food allergy. Dr. Adelman began his career as an Assistant Professor of Clinical Medicine in the Division of Allergy and Immunology at the University of California, San Francisco, School of Medicine, where he was also Director of Clinical Allergy and Immunology. He is also currently an Adjunct Professor of Medicine at UCSF, where he has taught and practiced at for more than 34 years, remaining on the faculty upon entering industry. He has also served on the editorial boards of the Journal of Clinical Immunology and Clinical Immunology, and as a clinical advisor to multiple bi...